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With over 17,000 articles published since 1966, the oral contra
ceptive pill is one of the most studied preventive health drugs.
Recent studies have shown many important findings related to the
noncontraceptive health benefits of the oral contraceptive pill in
cluding a reduction in ovarian cancer, endometrial cancer, pelvic
inflammatory disease, breast disease, and acne.
Ovarian Cancer
Ovarian cancer is the most common cancer of the reproductive
organs and is the fourth leading cause ofdeath in women after cancer
of the lung, breast, colon, and rectum. An estimated 27,000 cases of
ovarian cancer are diagnosed each year, and 15,000 deaths occur
yearly. Since ovarian cancer is difficult to detect and is generally
advanced atthe time ofdiagnosis, the 5-year survival rate is less than
45%)
Recent studies have shown that the risk of ovarian cancer de
creases significantly with use of the oral contraceptive pill. Risk
reduction has been shown to be 40% after 4 years, 53% after 8 years,
and 60% after 12 years of oral contraceptive use.2 Protection has
been shown to begin with 1 year of use arid persists from 10 to 19
years after the pill is stopped.3
Endometrial Cancer
Although endomethal cancer is the lowest cause of death from
pelvic cancer, it is the most commonly diagnosed. Among U.S.
women, 34,000 cases are diagnosed each year and 6,000 deaths
occur yearly. A recent analysis of 10 epidemiologic studies pub
lished between 1980 and 1994 found a significant decrease in
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endomethal cancer risk of 54% after 4 years, 66% after 8 years, and
72% after 12 years of oral contraceptive use.3 Protection against
endometrial cancer has been shown to begin with 1 year of use and
persists for at least 20 years after stopping the oral contraceptive
pill.4
Pelvic Inflammatory Disease
Pelvic inflammatory disease affects more than 1 million women
annually in the United States.5 Approximately 250,000 women
develop more serious sequelae each year including tubal damage,
chronic pelvic pam, ectopic pregnancy, and infertility.6In a hospital-
based-controlled study, a lower risk of pelvic inflammatory disease
was observed among women taking the oral contraceptive pill
continuously for at least 12 months compared to nonusers. In this
study a reduction of 60% in the rate of hospitalization for pelvic
inflammatory disease was observed.7
Bone Mineral Density
Women taking oral contraceptive pills may derive protection
against osteoporosis. Cross-sectional studies of posimenopausal
women have documented that prior users of the oral contraceptive
pill have greater bone density and that this protection increases with
longer duration of use.8A 12% increase in bone mineral density was
found in premenopausal women on the oral contraceptive pill
compared with nonusers, with the greatest increase occuring in
women who had used the pill for at least 10 years.9Osteoporosis has
also shown to be less common and to occur later in women who have
been on the oral contraceptive pill.’°
Benign Breast Disease
Studies have shown that after 2 years of oral contraceptive use
there was a reduction of 83% in the incidence of fibroadenomas and
53% in the incidence of fibrocystic disease.” Previous users were
found to have a reduction of 65% in the incidence of fibroadenomas
and 34% in the incidence of fibrocystic disease. Studies using the
lower dose oral contraceptive pills have shown a similar decrease in
the incidence of benign breast disease.’2
Concern that the oral contraceptive pill might increase breast
cancer continues to be prevalent among U.S. women. A recently-
published reanalysis ofnearly all of the epidemiologic data available
on breast cancer risk and the use of oral contraception included data
on 53,297 women with breast cancer and 100,239 controls in 25
countries’3 showed that the estimated cumulative risk of being
diagnosed with breast cancer was not significantly different among
women who had discontinued the oral contraceptive pill for more
than 10 years compared with women who had never been on the pill.
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The data indicated that oral contraceptive use slightly increased the
risk of breast cancer. Breast cancers diagnosed in women on the oral
contraceptive pill were found to be localized compared to nonusers,
and the survival rate in women on oral contraception was greater
than in nonusers.
Rheumatoid Arthritis
Most studies have shown a decrease in rheumatoid arthritis
among women on oral contraception. A recent case-controlled study
reported a 60% reduction in the relative risk of rheumatoid arthritis
in women on oral contraception with the greatest protection found
in those with a family history of the disease.’4A meta-analysis of the
literature suggests that oral contraception might not be protective
but may inhibit the disease’s progression.’5
Acne
Several studies have shown an improvement in acne in women on
the oral contraceptive pill. Most recently an oral contraceptive pill
was compared to a placebo to determine whether acne was improved
in women on the pill.’6Significant reductions in inflammatory acne
lesions and total lesions were noted in women using the triphasic
norgestimate/ethinyl estradiol (35 mcg) pill compared with women
taking a placebo. These findings resulted in the Food and Drug
Administration (FDA) relabeling the indications for the triphasic
norgestimate/ethinyl estradiol pill to include treatment for acne.
This represents the first time that the FDA has approved a
noncontraceptive indication for an oral contraceptive pill. At a
recent symposium, the authors of this study also presented data
showing that women on this triphasic pill actually lost weight
compared to women taking a placebo.’7
Conclusion
The oral contraceptive pill has been extensively studied for more
than 40 years, but only recently have studies been published show-
ing an overall improvement in health in women on oral contracep
tion. These health benefits are especially significant in older women
since the FDA no longer has an upper age limit for discontinuation
of the pill. The significance of the noncontraceptive benefits of the
oral contraceptive pill, which include a significant reduction in
ovarian cancer, endometrial cancer, pelvic inflammatory disease,
benign breast disease, and acne, have led many researchers and
physicians to advocate use of the pill even in women who do notneed
contraception.
References
1. American Cancer Society. Cancer Facts 5 Figures — I 996.
2. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United
States. Obstet Gynecoi 1 995;85:793-801.
3, Rosenberg L, PalmerJR, ZauberAG et al. A case-control study ot oral contraceptive use and invasive
epithelial ovarian cancer. Am J Epidemiol. 1 994;1 39:654-661.
4. JickSS, WalkerAM.lickH. Oral contraceptivesandendometrial cancer. AmJEpidemiot 1 994;1 39:654-
661.
5. Rofis RT, Galaid El, ZaidiAA: Pelvic inflammatory disease: Trends in hospitalizations and office visits,
1979 through 1988. Am J Obstet Gynecol 1992;1 66:983-989,
6. McCorrnack WM. Pelvic inflammatory disease. N EngIJ Med. 1994:330:115-119.
7. Passer LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic
inflammatory disease. Contraception. 199143:91-99.
8. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low
bone mass. Archlntern Med. 1991:151:1971-1976.
9. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol. 1996:174:15-20.
10. Enzelsberger H, Metka M, Heytrnanek 0, et al. Influence of oral contraceptive use on bone density in
climacteric women. Maturitas. 1988:9:375-352.
11. Brinton LA, Vessey MP, Flavel R, et at: Risk factors for benign breast disease. Am J epidemiol
1981113:203-214.
12. Charreau I, Plu-Bureau G, Bachelot A, et al: Oral contraceptive use and risk of benign breast disease
in a French case-control study of young women, EurJ Cancer Prevent 1993:2:147-152.
13. Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormonal contracep.
lives: collaborative reanalysis of individual data on 53 297 women wfth breast cancer from 54
epidemiological studies. Lancet. 1996;347:171 3-1727.
14. Hazes JMW, Dilkmans BAC, Var,denbroucke JP, et al. Reduction of the risk of rheumatoid arthritis
among women who take oral contraceptives. Arthr Rheum. 1990:33:173-179.
15. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthrfiis:
anoverviewoftheanalyticalepidemiologicalstudies using meta-arralysis. JClin Epidemlo. 1990;43:1221-
1227.
16. Redmond GP, Olson WH, Uppman JS. Treatment of acne vulgaris: a randomized placebo-controlled
trial, Obstet Gynecoi I 997;89(4);61 5-622.
17. Double-blind, mullicenter, placebo-controlled studies evaluating the efficacy of Ortho Tri-Cyclen R in
the treatment of moderate acne vulgaris. Report NO. CA-R0005. 1995. Data on file, Ortho-McNeil
Pharmaceutical.
HAWAII MEDICAL JOURNAL, VOL 57. AUGUST 1998
592
